期刊文献+

二甲双胍临床应用新进展 被引量:8

New clinical application of Metformin
下载PDF
导出
摘要 二甲双胍能改善糖脂代谢,改善胰岛素抵抗,减轻体质量,对心血管有良好的保护作用,是众多口服降糖药物中的一线用药,是一线治疗的最佳选择。近年来对二甲双胍降糖作用以外的临床应用研究不断深入,已被应用于多囊卵巢综合征,非酒精性脂肪性肝病等多种疾病的治疗。 Metformin(Met) can improve glycometabolism and lipid metabolism, ameliorate insulin resistance, reduce body weight, and has protective effects on cardiovascular system. Metformin is usually the first-line medication used for treatment of type 2 diabetes mellitus. In recent years, the researches on the clinical application of metformin is not only limited to its role as one of oral hypoglycemic agent, but also the application of the therapy of other diseases , such as polycystic ovarian syndrome, nonalcoholic fatty liver disease and so on. In the near future, more and more studies will be performed.
出处 《国际内科学杂志》 CAS 2008年第10期578-581,共4页 International Journal of Internal Medicine
关键词 二甲双胍 临床应用 糖尿病 2型 Metformin Clinical application Diabetes mellitus, type 2
  • 相关文献

参考文献19

  • 1Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome-a new worldwide definition. Lancet, 2005, 366 (9491) :1059-1062.
  • 2Misra P, Chakrabarti R. The role of AMP kinase in diabetes. Indian J Med Res, 2007,125(3) :389-398.
  • 3Yang J, Holman GD. Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis. Endocrinology, 2006,147 (6) : 2728-2736.
  • 4Lund SS, Tarnow L, Frandsen M, et al. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in nonobese patients with type 2 diabetes. Eur J Endocrinol,2008, 158( 1 ) :35-46.
  • 5Ren T, He J, Jiang H,et al. Mefformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-al- pha or isoproterenol. J Mol Endocrinol, 2006,37 ( 1 ) : 175- 183.
  • 6Eguchi K, Tomizawa H, Ishikawa J, et al. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res, 2007,30( 1 ) :23- 30.
  • 7Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA In mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab, 2004,89(10) :5043-5047.
  • 8Saenz A, Fernandez-Esteban I, Matair A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2005, (3) : CD002966.
  • 9Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2006,29 (8) : 1963-1972.
  • 10Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab, 2006, 91 ( 6 ) : 2074-2080.

同被引文献48

引证文献8

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部